Prestige BioPharma Limited (950210.KS)
KSE · KRW · Healthcare · Biotechnology
₩5,050 (-0.20%) as of
Key statistics
- Market cap
- 303.49B
- Dividend yield
- 0.00%
- 52-week range
- 4,940.00 – 14,120.00
- Beta
- 0.35
- Revenue (TTM)
- 26.07B
- Profit margin
- 0.00%
- Volume
- 72.18k
About Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer; PBP1710, a first-in-class antibody that is in preclinical trials for the treatment of solid tumor and fibrosis; and IDC007, a bispecific antibody for the treatment of CRS. In addition, the company is developing IDC005, IDC001, IDC002, IDC003, IDC008, and IDC009 bispecific antibodies; IDC111, a first-in-class antibody; IDC112, first-in-class antibody; IDC113 first-in-class antibody; IDC332, IDC331, IDC333, and IDC334 novel concept antibodies; and IDC441, an ADC antibody for the treatment of solid tumours. Additionally, it offers biosimilars for immunology, endocrinology, oncology, haematology, and dermatology diseases. Further, it develops IDC221, a PAUF-based pancreatic cancer diagnostic solution for the treatment of pancreatic cancers. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Singapore, Singapore
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.